Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein

Cholangiocarcinoma (CCA) is a destructive malignancy with limited responsiveness to conventional chemotherapy. Although angiotensin receptor blockers (ARBs) have gained attention for their potential anticancer activity, little is known about their effects on CCA. The transcriptional co-activator, Yes-associated protein (YAP) is a critical oncogene in several cancers, including CCA. Following recent evidence showing that YAP is regulated by angiotensin II (AT-II), we investigated the effects of an ARB, losartan, on two human CCA cell lines (KKU-M213 and HuCCT-1) with regards to YAP oncogenic regulation.

Source: Cancer Letters - July 19, 2018 Category: Cancer & Oncology Authors: Soichiro Saikawa, Kosuke Kaji, Norihisa Nishimura, Kenichiro Seki, Shinya Sato, Keisuke Nakanishi, Koh Kitagawa, Hideto Kawaratani, Mitsuteru Kitade, Kei Moriya, Tadashi Namisaki, Akira Mitoro, Hitoshi Yoshiji Tags: Original Articles Source Type: research